Synchron Secures US$200 Million in Series D Financing
Synchron has successfully raised US$200 million in a Series D financing round aimed at speeding up the commercialisation of its first-generation Stentrode brain-computer interface (BCI) platform. The funding will also support development of an advanced "next-generation, transcatheter, high-channel whole-brain interface."
Advancing Clinical Trials and Commercial Launch
The company plans to use the capital to accelerate pivotal trials and prepare for the commercial launch of the Stentrode BCI system. Synchron highlighted in a press release that this funding will enable continued hiring of engineers, neuroscientists, and operators to push forward the next-generation BCI technology.
Funding Round and Investors
- The Series D round was led by Double Point Ventures.
- Existing investors include ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
- New participants are the Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
Total Funding Overview
This latest round brings Synchron's total capital raised to US$345 million, as per the company’s recent announcement.
“Bolstered by this Series D funding, Synchron will continue hiring engineers, neuroscientists and operators to advance the next generation of BCIs.”
Summary: Synchron’s $200 million Series D funding marks a significant step toward bringing advanced brain-computer interface technologies closer to commercial reality, backed by strong investor support.